Skip to main content
Smart Investors Daily
LP

NASDAQ · LPAAU

Launch One Acquisition Corp. Unit

Financial Services · Shell Companies

$11.05

Down-$0.18 (-1.63%)

Updated Nov 8, 2026, 11:10 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
349.92M
P/E ratio
27.52
Dividend yield
0.00%
52-week range
$10.74 – $11.49
Volume
163
Avg. volume
351

Price performance · LPAAU

LPAAU price history

1M range · 7 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

LPAAU closed at $11.05 after 7 trading sessions, up 2.13% for the selected period.

Last close
$11.05
Period change
+2.13%
Period low
$10.82
Period high
$11.26
Daily close
View OHLC price history
LPAAU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$11.05$11.05$11.05$11.05163
Oct 30, 2026$11.14$11.14$11.14$11.14215
Oct 27, 2026$11.13$11.13$11.13$11.13142
Oct 26, 2026$11.00$11.26$11.00$11.26410
Oct 21, 2026$11.00$11.00$11.00$11.00102
Oct 15, 2026$10.83$10.83$10.83$10.83160
Oct 13, 2026$10.82$10.82$10.82$10.82330

Latest LPAAU news

The latest Smart Investors Daily articles mentioning LPAAU.

LPAAU research

Overview

Company profile and research snapshot.

Company profile

Launch One Acquisition Corp is a blank check company.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 13, 2026

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseasesHAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.